A great morning of presentations at our annual post-ASH meeting hosted by Dr. Natalia Neparidze. Thoughtful questions & excellent talks highlighting new data and exciting #clinicaltrials for patients with hematologic malignancies.
@yale-hematology.bsky.social #ASH25

Take the first step toward accelerating your hematology career! Join ASH and Malaysian Society of Haematology next month at Highlights of ASH in Asia-Pacific.

Experience world-class knowledge and networking close to home. 🌏

Register now: https://ow.ly/ebcO50YrYMg #Hemesky #Medsky #ASH25

Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405) BackgroundMantle cell lymphoma (MCL) is an incurable form of aggressive non-Hodgkin lymphoma. Treatment choice at diagnosis is based on tolerability o…

#FindingsFriday: ICYMI, new data from @precogonc.bsky.social PrE0405, presented at #ASH25, showed that treatment with BR-VEN led to high response rates & promising CR rates for older patients w/ mantle cell #lymphoma. More: bit.ly/4aReE69 #MCL

Is it time to redefine the "gold standard" for AML chemotherapy?

For decades, intensive induction chemotherapy (IC) has been the default for fit adults with newly diagnosed AML. However, the Phase II PARADIGM study results suggest a new path forward. 👉Full abstract from #ASH25: go.nmdp.org/3MxtIO2

ASH 2025:  Lymphoma Treatment Strategies and a Novel Prognostic Tool Studies presented at the ASH Annual Meeting 2025 highlighted a novel prognostic approach and emerging treatment strategies in lymphoma.

Finally, our in-depth #ASH25 coverage of #lymphoma looked at treatment strategies and a new prognostic tool.

ASH 2025: Refining Chemotherapy and Biomarker-Adapted Strategies in AML The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

Our in-depth #ASH25 coverage also looked at treatment strategies in #AML.

ASH 2025: New Combinations Drive Advances in Multiple Myeloma The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Also from #ASH25, new combinations drive advances in multiple myeloma.

ASH 2025: Refining the Modern Management of CLL in the Era of Targeted Therapies Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Next, dive into some of our in-depth coverage from #ASH25, including a feature on management of #CLL in the era of targeted therapies.

Citizens a maintenu sa notation "Market Outperform" pour #Cellectis 🧬 avec un objectif de cours de 8$, anticipant une mise à jour clinique lors de la réunion de l’American Society of Hematology #ASH25

Elevate your practice with the latest breakthroughs in #hematology. Discover cutting-edge data in this collection of On Location video interviews from #ASH25, including new research in #MMsm, #CLL, and more: https://ow.ly/GqII50Y8i2V
Wiley Clinical and Health
#HemeSky #MedSky

Significant Barriers to Health Literacy Exist for Patients With Thalassemia Researchers determined there may be overestimation of disease understanding and barriers to health literacy among patients with thalassemia.

"Many patient populations with hereditary conditions such as #thalassemia have lived w the disease for their entire life, so it’s not surprising that they report high levels of confidence in health-related knowledge" @devasharma.bsky.social of @vumedicine.bsky.social.

https://bit.ly/4t4hyN6

#ASH25

From conference data to clinical impact. Amir T. Fathi, MD shares key leukemia takeaways from American Society of Hematology 2025, highlighting what new data may mean for patients with AML and CML.

🎧 Listen to the full discussion:https://bit.ly/3NN1bUW

#ASH25 #MedicalEducation

New publication 📝 Phase I data presented at #ASH25 show that surovatamig demonstrated tolerability and achieved CR rates of 86–100% across dose cohorts in heavily pretreated R/R FL patients

Learn more: https://loom.ly/LAddsXI

#lymphoma #lymsm #MedNews #MedEd

Take the first step toward building regional partnerships at Highlights of ASH in the Mediterranean, Middle East, and North Africa! 🌍

Connect with #hematology experts as you explore the clinical application of new #ASH25 evidence: https://ow.ly/liNC50Y0G1w #Hemesky #Medsky

The January issue is out now! Issue highlights include meeting coverage and reports from #ASH25, a feature on #patient support programs, updates on international guidelines for #pediatric #AcuteMyeloidLeukemia #AML, and more. See the full lineup here: https://ow.ly/tgpq50Y0C89

BrECADD May Be a Standard Therapy Option in Newly Diagnosed, Advanced-Stage HL - Hematology Advisor Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting.

Among patients with newly diagnosed, advanced-stage classical #HodgkinLymphoma, the novel BrECADD combination may represent a new standard treatment option. Presented at #ASH25 by @ferdinandusj.bsky.social. From @cancertherapyadv.bsky.social.

https://bit.ly/45HWHVP

#ASH2025 #lymsm

CAR T-cell therapy works. Recovery is the challenge.
New research shows a stem cell boost may help restore blood counts faster after CAR T-cell treatment. Learn more from IMF Scientific Advisory Board experts:
https://mmsm.link/4boNwxd


#IMFSAB #IMFASH25 #ASH25

Advance your career with world-class ASH content in Kuala Lumpur! 🧠

At Highlights of ASH in Asia-Pacific, ASH and the Malaysian Society of Haematology will bring leading #hematology experts and breakthrough #ASH25 research to you.

Secure your spot: https://ow.ly/zX9O50XXik9 #Hemesky #Medsky

Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL | OncLive Nemtabrutinib plus venetoclax showed early activity and manageable safety in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/nemtabr...

For those facing extramedullary myeloma, new research offers real hope. Studies show that combining two immune therapies may improve outcomes, even in advanced disease. Learn more from IMF experts: https://mmsm.link/4boNwxd

#IMFSAB #IMFASH25 #ASH25

Explore all of the abstracts from our 67th Annual Meeting and see what's driving the field of hematology forward today: ashpublications.org/blood/issue/... #ASH25 #Abstracts

New IMF research shows that acting early in smoldering myeloma may help stop cancer before it starts. Results from the GEM-CESAR study highlight how early treatment and close monitoring can protect patients and quality of life. https://mmsm.link/4boNwxd

#IMFSAB #IMFASH25 #ASH25 #IMFBSRI

New data📝Phase II preliminary results, presented by Anita Kumar at #ASH25, show the BOVen triplet combination achieved a 98% metabolic response rate in older patients with MCL, with a 2-year PFS of 86% and OS of 92%.

Learn more: https://loom.ly/B8pRi7c

#lymphoma #lymsm #MedNews #MedEd

Breakthrough Myeloma Abstracts: IMF Scientific Advisory Board and International Myeloma Working Group Members Take Center Stage at ASH 2025 The IMF takes you to the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, where members of the IMF SAB and IMWG presented breakthrough abstracts in myeloma research.

Résumés de #Breakthrough 👑 #Myelome 🩸 : le Conseil consultatif scientifique du FMI et les membres du Groupe de travail international sur le #MyélomeMultiple 🩸 occupent le devant de la scène à l’ #ASH25

www.myeloma.org/blog/breakth...

BrECADD May Be a Standard Therapy Option in Newly Diagnosed, Advanced-Stage HL Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting. Researchers determined the BrECADD combination therapy may be a new standard treatment option for patie...

Among patients with newly diagnosed, advanced-stage classical #HodgkinLymphoma, the novel BrECADD combination may represent a new standard treatment option. Presented at #ASH25, from @hematologyadvisor.bsky.social.

https://bit.ly/49lkOdZ

#lymsm

The top 10 most impactful myeloma breakthroughs in CAR T-cell therapy and bispecific antibodies from ASH. Watch now: https://mmsm.link/4qeZrlU


#ASH25 #IMFASH25 #ASKTHEIMF

Test your knowledge and earn CME credit! If you don’t already have it, now is the perfect time to get our Hematology 2025 ASH Education Program. Digital access is FREE for members and #ASH25 attendees. Anyone can purchase digital and/or print editions here apps.hematology.org/store/produc...

See what's to come in this month's issue! Editor-in-Chief Bethany Samuelson Bannow, MD, MCR (she/her) shares what readers can expect, including coverage from #ASH25, a feature on #patient assistance programs, a challenging case of refractory #Hodgkin #lymphoma, and more: https://ow.ly/Bnww50XT7Uw

Éti-cel dans le #Lymphome non-hodgkinien ( #LNH 🩸) R/R #NATHALI_01

S'appuyant sur les données préliminaires de phase 1 présentées lors du congrès annuel de l' #ASH25, #Cellectis se concentre sur la maximisation de l'impact clinique de son produit candidat à double #CAR_Tcell 🧬

From #ASH25: We break down the 10 most impactful myeloma breakthroughs, including advances in CAR T-cell therapy and bispecific antibodies and what this latest research means for people living with myeloma. Watch now: mmsm.link/4qeZrlU

#IMFASH25 #ASKTHEIMF
@jmikhaelmd.bsky.social